Table 2:
Characteristics of study population
| Variable | N (%) |
|---|---|
| Number of patients | 124 |
| Number of centers | 34 |
| Patient-related variables | |
| Age at HSCT, years | |
| Median (range) | 9 (1–21.5) |
| 0–9 | 67 (54) |
| 10–21 | 57 (46) |
| Sex | |
| Male | 71 (57) |
| Female | 53 (43) |
| Race | |
| Caucasian | 102 (82) |
| Non-Caucasian | 19 (15) |
| Declined/Unknown | 3 ( 2) |
| Performance Score | |
| ≥ 90 | 102 (82) |
| < 90 | 22 (18) |
| HCT-CI | |
| No comorbidity | 70 (56) |
| 1–2 | 31 (25) |
| ≥ 3 | 23 (18) |
| Disease-related variables | |
| Disease status | |
| CR1 | 67 (54) |
| CR2 | 46 (37) |
| Therapy-related AML at any stage | 11 ( 9) |
| Cytogenetics scoring | |
| Favorable | 10 (8) |
| Intermediate | 69 (56) |
| Poor | 41 (33) |
| Missing | 4 ( 3) |
| Transplant-related variables | |
| Graft type | |
| BM | 66 (53) |
| PBSC | 11 ( 9) |
| Single CBU | 38 (31) |
| Double CBU | 9 ( 7) |
| Donor type | |
| HLA identical sibling | 25 (20) |
| ≥ 7/8 HLA matched related | 5 ( 4) |
| ≥ 7/8 HLA matched unrelated | 94 (76) |
| Recipient CMV | |
| Negative | 55 (44) |
| Positive | 69 (56) |
| Conditioning regimen | |
| Busulfan-based | 99 (80) |
| TBI-based | 16 (13) |
| Treosulfan-based | 9 ( 7) |
| GVHD prophylaxis | |
| Post-HSCT Cyclophosphamide | 2 ( 2) |
| CNI + mycophenolate mofetil (MMF) | 55 (44) |
| CNI + methotrexate (MTX) | 59 (48) |
| CNI alone or with other | 8( 6) |
| Serotherapy | |
| Anti-thymocyte globulin (ATG) + alemtuzumab | 2 ( 2) |
| ATG alone | 56 (45) |
| alemtuzumab alone | 3 ( 2) |
| None | 63 (51) |